Ultragenyx Pharmaceutical Inc.
RARE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.5B
$15.30
▲ +3.03%
P/E
-5.58
Mkt Cap
$1.5B
52-Wk Range
$13.81–$39.89
52-Week Range
$13.81 - $39.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 51.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-29.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RARE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of -$0.90 vs -$1.22 consensus (+26.2% surprise). Revenue of $214.0M vs $183.1M expected (+16.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+26.2%
Revenue trend · last 2Q
—
+29%
Q1 26
Q2 26
$136.0M
$214.0M
Margins · last 2Q
Gross
84.1%
Operating
-35.0%
Profit
-43.0%
Wall Street consensus
10 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
—
Latest: Barclays · Sep 4, 2026
vs Industry
How RARE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.